SCHEMBL2748643

SCHEMBL2748643

Nc1ncc(-c2cccc(O)c2)cc1-c1nc2ccccc2s1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.64
SMN1; SMN2 Q16637 4/20 0.64
POLB P06746 2/20 0.64
NFKB1 P19838 2/20 0.64
NFKB2 Q00653 2/20 0.64
RELA Q04206 2/20 0.64
HSD17B10 Q99714 2/20 0.64
LMNA P02545 2/20 0.64
TP53 P04637 1/20 0.64
NPC1 O15118 6/20 0.53
KDM4E B2RXH2 6/20 0.53
MAPT P10636 5/20 0.53
NPSR1 Q6W5P4 1/20 0.53
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
ALDH1A1 P00352 3/20 0.50
GAA P10253 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
APP P05067 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2747422 0.85 MAP4K4 (0.58) RAB9ASMN1; SMN2POLBNFKB1NFKB2
SCHEMBL2750253 0.84 FYN (0.54) RAB9ANFKB1NFKB2RELANPC1
SCHEMBL2748849 0.82 CDK8 (0.50) RAB9ASMN1; SMN2POLBTP53NPC1
SCHEMBL2748893 0.81 MKNK2 (0.64) RAB9ASMN1; SMN2NFKB1NFKB2RELA
SCHEMBL2749479 0.81 FFAR1 (0.55) RAB9ASMN1; SMN2POLBNFKB1NFKB2
SCHEMBL2747417 0.81 CDK8 (0.49) RAB9ASMN1; SMN2POLBTP53NPC1
SCHEMBL2749378 0.80 MAP4K4 (0.65) RAB9ASMN1; SMN2POLBNFKB1NFKB2
SCHEMBL2749502 0.80 BCL2 (0.48) RAB9ASMN1; SMN2POLBNFKB1NFKB2
SCHEMBL2750324 0.80 ILK (0.65) RAB9ASMN1; SMN2POLBNFKB1NFKB2
SCHEMBL2748144 0.79 CHEK2 (0.62) RAB9ANPC1MEN1KMT2AFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 RAB9A 1549/4885SMN1; SMN2 763/4885POLB 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.